Back to top
more

Ascendis Pharma (ASND)

(Delayed Data from NSDQ)

$135.90 USD

135.90
226,133

-1.03 (-0.75%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $135.97 +0.07 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ASND

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Ascendis Pharma AS falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 432 775 807 821 670
Receivables 60 27 27 8 6
Notes Receivable 0 0 0 0 0
Inventories 226 138 89 0 0
Other Current Assets 42 33 30 16 9
Total Current Assets 761 973 953 845 685
Net Property & Equipment 120 136 149 124 50
Investments & Advances 6 32 173 142 17
Other Non-Current Assets 2 2 2 2 0
Deferred Charges 0 0 0 0 0
Intangibles 5 5 6 7 4
Deposits & Other Assets 0 0 0 0 2
Total Assets 894 1,148 1,284 1,119 758
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 102 106 70 25 31
Current Portion Long-Term Debt 12 27 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 2 6 0 0 0
Other Current Liabilities 81 41 48 27 16
Total Current Liabilities 214 180 119 60 54
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 578 509 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 168 181 4 4 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,051 871 238 161 89
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 8 8 9 8 7
Capital Surplus 2,298 2,226 2,494 1,975 1,257
Retained Earnings -2,465 -1,960 -1,673 -1,177 -685
Other Equity 1 4 241 152 89
Treasury Stock 0 0 26 0 0
Total Shareholder's Equity -158 277 1,045 958 669
Total Liabilities & Shareholder's Equity 894 1,148 1,284 1,119 758
Total Common Equity -158 277 1,045 958 669
Shares Outstanding 57.70 57.00 56.80 53.40 42.10
Book Value Per Share -2.73 4.87 18.41 17.94 15.89

Fiscal Year End for Ascendis Pharma AS falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 432 496 470 629
Receivables NA 60 54 39 37
Notes Receivable NA 0 0 0 0
Inventories NA 226 206 183 162
Other Current Assets NA 42 42 47 42
Total Current Assets NA 761 798 739 869
Net Property & Equipment NA 120 137 137 137
Investments & Advances NA 6 9 15 24
Other Non-Current Assets NA 2 2 2 2
Deferred Charges NA 0 0 0 0
Intangibles NA 5 5 5 5
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 894 950 898 1,037
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 102 132 133 141
Current Portion Long-Term Debt NA 12 13 29 27
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 2 7 6 7
Other Current Liabilities NA 81 64 41 37
Total Current Liabilities NA 214 232 210 213
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 578 598 523 515
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 103 95 130
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,051 1,030 828 858
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 8 8 8 8
Capital Surplus NA 2,298 2,309 2,306 2,270
Retained Earnings NA -2,465 -2,399 -2,245 -2,101
Other Equity NA 1 2 2 3
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -158 -80 71 179
Total Liabilities & Shareholder's Equity NA 894 950 898 1,037
Total Common Equity 0 -158 -80 71 179
Shares Outstanding 58.20 57.70 57.60 57.30 57.10
Book Value Per Share 0.00 -2.73 -1.39 1.23 3.14